ABT _sold_$2.2B_of_COVID-19_diagnostics_in_1Q21 (down from $2.4B in 4Q20): https://abbott.mediaroom.com/2021-04-20-Abbott-Reports-First-Quarter-2021-Results Non-GAAP EPS guidance for 2021 remains >=$5.00 (+37%, or more, relative to 2020). 1Q21 one-page graphic: https://www.abbottinvestor.com/static-files/f172ced6-f814-490b-8e5c-3be152119058